ACOR Stock Summary and Trading Ideas (Acorda Therapeutics | NASDAQ:ACOR)

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.

Acorda Therapeutics trades on the NASDAQ stock market under the symbol ACOR.

As of April 18, 2024, ACOR stock price was flat at $0.66 with million shares trading.

ACOR has a beta of 3.83, meaning it tends to be more sensitive to market movements. ACOR has a correlation of 0.03 to the broad based SPY ETF.

ACOR has a market cap of $821,027.00. This is considered a Sub-Micro Cap stock.

In the last 3 years, ACOR stock traded as high as $127.20 and as low as $.61.

ACOR has underperformed the market in the last year with a price return of -93.6% while the SPY ETF gained +22.3%. ACOR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -96.0% and -66.8%, respectively, while the SPY returned +6.1% and -3.8%, respectively.

ACOR support price is $.60 and resistance is $.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACOR stock will trade within this expected range on the day.